Scientists developing chewing gum that could reduce SARS-CoV-2 transmission

05 December,2021 10:52 AM IST |  New York  |  IANS

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable, indicates the study published in the journal Molecular Therapy

Photo for representational purpose. Picture Courtesy/iStock


A chewing gum laced with a plant-grown protein serves as a "trap" for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, finds a new study.

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable, indicates the study published in the journal Molecular Therapy.

"SARS-CoV-2 replicates in the salivary glands, and we know that when someone d sneezes, coughs, or speaks some of that virus can be expelled and reach others," said researcher Henry Daniell from the University of Pennsylvania in the US.

"This gum offers an opportunity to neutralise the virus in the saliva, giving us a simple way to possibly cut down on a source of disease transmission," Daniell added.

To test the chewing gum, the team grew angiotensin-converting enzyme 2 (ACE2) in plants, paired with another compound that enables the protein to cross mucosal barriers and facilitates binding, and incorporated the resulting plant material into cinnamon-flavoured gum tablets.

Incubating samples obtained from nasopharyngeal swabs from Covid-positive patients with the gum, they showed that the ACE2 present could neutralise SARS-CoV-2 viruses.

Those initial investigations were followed by others, in which viruses, less-pathogenic than SARS-CoV-2, were modified to express the SARS-CoV-2 spike protein.

The team observed that the gum largely prevented the viruses or viral particles from entering cells, either by blocking the ACE2 receptor on the cells or by binding directly to the spike protein.

The research team is currently working toward obtaining permission to conduct a clinical trial to evaluate whether the approach is safe and effective when tested in people infected with SARS-CoV-2.

Also Read: Nagaland: Villagers killed in firing by security forces in case of 'mistaken identity'

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!
Coronavirus tech news
Related Stories